Articles with "p53 wild" as a keyword



Photo by rayhennessy from unsplash

Heterochiral dipeptide d‐phenylalanyl‐ l‐phenylalanine (H‐DPhe‐LPhe‐OH) as a potential inducer of metastatic suppressor NM23H1 in p53 wild‐type and mutant cells

Sign Up to like & get
recommendations!
Published in 2022 at "Molecular Carcinogenesis"

DOI: 10.1002/mc.23465

Abstract: In recent years, significant progress has been made to the use‐case of small peptides because of their diversified edifice and hence their versatile application scope in cancer therapy. Here we identify the heterochiral dipeptide H‐DPhe‐LPhe‐OH… read more here.

Keywords: heterochiral dipeptide; dphe lphe; p53 wild; p53 ... See more keywords
Photo by matmacq from unsplash

Ginkgo Biflavones Cause p53 Wild-Type Dependent Cell Death in a Transcription-Independent Manner of p53.

Sign Up to like & get
recommendations!
Published in 2023 at "Journal of natural products"

DOI: 10.1021/acs.jnatprod.2c00959

Abstract: Ginkgo biloba, as a medicinal plant in both traditional and western medicine, emerged as a potential therapeutic agent for the management of a variety of diseases, but ginkgo biflavones (bilobetin, isoginkgetin, and ginkgetin) application in… read more here.

Keywords: cell death; ginkgo biflavones; p53 wild; p53 ... See more keywords
Photo from archive.org

MK-8242 Is Active in Patients with p53 Wild-Type Advanced Solid Tumors.

Sign Up to like & get
recommendations!
Published in 2017 at "Cancer discovery"

DOI: 10.1158/2159-8290.cd-rw2017-047

Abstract: The MDM2 inhibitor MK-8242 is tolerable in patients with liposarcoma and other advanced solid tumors. read more here.

Keywords: solid tumors; advanced solid; p53 wild; active patients ... See more keywords
Photo from wikipedia

METTL14 modulates glycolysis to inhibit colorectal tumorigenesis in p53‐wild‐type cells

Sign Up to like & get
recommendations!
Published in 2023 at "EMBO Reports"

DOI: 10.15252/embr.202256325

Abstract: The frequency of p53 mutations in colorectal cancer (CRC) is approximately 40–50%. A variety of therapies are being developed to target tumors expressing mutant p53. However, potential therapeutic targets for CRC expressing wild‐type p53 are… read more here.

Keywords: p53 crc; p53; p53 wild; wild type ... See more keywords